Coligation of the B cell receptor with complement receptor type 2 (CR2/CD21) using its natural ligand C3dg: Activation without engagement of an inhibitory signaling pathway
被引:70
作者:
Lyubchenko, T
论文数: 0引用数: 0
h-index: 0
机构:Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80220 USA
Lyubchenko, T
dal Porto, J
论文数: 0引用数: 0
h-index: 0
机构:Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80220 USA
dal Porto, J
Cambier, JC
论文数: 0引用数: 0
h-index: 0
机构:Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80220 USA
Cambier, JC
Holers, VM
论文数: 0引用数: 0
h-index: 0
机构:Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80220 USA
Holers, VM
机构:
[1] Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80220 USA
[2] Univ Colorado, Hlth Sci Ctr, Dept Immunol, Denver, CO 80220 USA
[3] Natl Jewish Med & Res Ctr, Dept Immunol, Denver, CO USA
C3dg is a cleavage product of the C3 component of complement that can facilitate the coligation of the complement receptor 2 (CR2/CD21) with the BCR via C3dg/Ag complexes. This interaction can greatly amplify BCR-mediated signaling events and acts to lower the threshold for B cell activation. Although previous studies have used anti-CR2 Abs, or used chimeric Ags in the context of BCR transgenic mice as surrogate CM-containing ligands, we have used a physiological form of C3d to study signaling in B cells from wild-type C57BL/6 mice. We find that while CR2-enhanced BCR signaling causes intracellular Ca2+ mobilization and total pTyr phosphorylation of an intensity comparable to optimal BCR ligation using anti-IgM Abs, it does so with limited activation of inhibitory effectors (such as CD22, Src homology region 2 domain containing phosphatase 1, and SHIP-1) and without substantial receptor cross-linking. In summary, we demonstrate that CR2-enhanced BCR signaling may proceed not only through the previously described amplification of positive signaling pathways, but is potentially augmented by a lack of normal inhibitory/ feedback signaling.
机构:
Univ Utah, Sch Med, Dept Pathol, Div Cell Biol & Immunol, Salt Lake City, UT 84132 USAUniv Utah, Sch Med, Dept Pathol, Div Cell Biol & Immunol, Salt Lake City, UT 84132 USA
Chakravarty, L
;
Zabel, MD
论文数: 0引用数: 0
h-index: 0
机构:
Univ Utah, Sch Med, Dept Pathol, Div Cell Biol & Immunol, Salt Lake City, UT 84132 USAUniv Utah, Sch Med, Dept Pathol, Div Cell Biol & Immunol, Salt Lake City, UT 84132 USA
Zabel, MD
;
Weis, JJ
论文数: 0引用数: 0
h-index: 0
机构:
Univ Utah, Sch Med, Dept Pathol, Div Cell Biol & Immunol, Salt Lake City, UT 84132 USAUniv Utah, Sch Med, Dept Pathol, Div Cell Biol & Immunol, Salt Lake City, UT 84132 USA
Weis, JJ
;
Weis, JH
论文数: 0引用数: 0
h-index: 0
机构:
Univ Utah, Sch Med, Dept Pathol, Div Cell Biol & Immunol, Salt Lake City, UT 84132 USAUniv Utah, Sch Med, Dept Pathol, Div Cell Biol & Immunol, Salt Lake City, UT 84132 USA
机构:
Univ Utah, Sch Med, Dept Pathol, Div Cell Biol & Immunol, Salt Lake City, UT 84132 USAUniv Utah, Sch Med, Dept Pathol, Div Cell Biol & Immunol, Salt Lake City, UT 84132 USA
Chakravarty, L
;
Zabel, MD
论文数: 0引用数: 0
h-index: 0
机构:
Univ Utah, Sch Med, Dept Pathol, Div Cell Biol & Immunol, Salt Lake City, UT 84132 USAUniv Utah, Sch Med, Dept Pathol, Div Cell Biol & Immunol, Salt Lake City, UT 84132 USA
Zabel, MD
;
Weis, JJ
论文数: 0引用数: 0
h-index: 0
机构:
Univ Utah, Sch Med, Dept Pathol, Div Cell Biol & Immunol, Salt Lake City, UT 84132 USAUniv Utah, Sch Med, Dept Pathol, Div Cell Biol & Immunol, Salt Lake City, UT 84132 USA
Weis, JJ
;
Weis, JH
论文数: 0引用数: 0
h-index: 0
机构:
Univ Utah, Sch Med, Dept Pathol, Div Cell Biol & Immunol, Salt Lake City, UT 84132 USAUniv Utah, Sch Med, Dept Pathol, Div Cell Biol & Immunol, Salt Lake City, UT 84132 USA